The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 09:27 ET

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16 01:21 ET

Shandong Xinhua Pharmaceutical Eyes Stake in Nutritional Oil Refining Firm

MT NewswiresDec 10 02:03 ET

Announcement highlights | Longfor Group's sales exceeded 90 billion yuan this year; Mao Geping announced the lottery results, listed this morning.

In the first 11 months, longfor group achieved a total contract sales amount of 93 billion yuan, with contract sales of 8.5 billion yuan in November; cspc pharma's application for marketing approval for SYHX2011 to treat advanced breast cancer was accepted.

cls.cnDec 9 18:57 ET

SHANDONG XINHUA (00719) intends to acquire no more than 75% of the equity of Noah Saint New (Taicang) Biotechnology to improve the Omega-3 Industry Chain.

Shandong Xinhua (00719) announced that to improve the group's industry chain and supply chain, it is promoting the high-quality development of the health industry...

Zhitong FinanceDec 9 06:30 ET

Express News | Shandong Xinhua Pharmaceutical - Novosanaeuropeb.v. to Sell Not More Than 75% of Novosana (Taicang) Co

ReutersDec 9 06:22 ET